# ESG401

Source: https://onco.cc/drugs/esg401/  
OnCo record `esg401` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ESG401 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.

## Summary

ESG401 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06732323 (A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer) and NCT06383767 (A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer), in triple-negative breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06732323, plans to enrol 504 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of ESG401: https://clinicaltrials.gov/search?intr=ESG401
- Sponsor page: https://www.qilu-pharma.com

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- trials: [A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer](https://onco.cc/trials/nct06383767/), [A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct06732323/)

---
JSON: https://onco.cc/api/v1/entities/esg401.json